Biogen has completed its $800 million acquisition of Nightstar Therapeutics (NST).
The deal – originally announced in March – has added two mid- to late-stage clinical assets to Biogen’s pipeline alongside preclinical programmes in ophthalmology.
“Today marks a significant achievement for Biogen,” said CEO Michel Vounatsos.
“The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities.
“We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”